These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23676598)

  • 1. Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Nagano S; Mori M; Kato A; Ono Y; Aoki K; Arima H; Takiuchi Y; Tabata S; Yanagita S; Matsushita A; Ishikawa T; Imai H; Takahashi T
    Intern Med; 2013; 52(10):1101-5. PubMed ID: 23676598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
    Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
    Kristinsson SY; Landgren O; Rajkumar VS
    Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 8. [Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
    Fuchida S; Okano A; Hatsuse M; Murakami S; Haruyama H; Shimazaki C
    Rinsho Ketsueki; 2012 Nov; 53(11):1937-9. PubMed ID: 23257677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part II: role of maintenance therapy in transplant-ineligible patients.
    Palumbo A; Mina R
    J Natl Compr Canc Netw; 2013 Jan; 11(1):43-9. PubMed ID: 23307980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
    Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
    Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
    Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
    Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Takeda Y; Sakaida E; Nakaseko C
    Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplants for the elderly in myeloma.
    Morgan GJ
    Blood; 2013 Aug; 122(8):1332-4. PubMed ID: 23970352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
    Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.